Literature DB >> 26874214

Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant.

Ivan Jelcic1, Ilijas Jelcic1, Christian Kempf1, Fabienne Largey1, Raquel Planas1, Sven Schippling1, Herbert Budka2, Mireia Sospedra1, Roland Martin1.   

Abstract

OBJECTIVE: Symptomatic infections of the central nervous system (CNS) with JC polyomavirus (JCV) usually occur as a result of immunocompromise and manifest as progressive multifocal leukoencephalopathy (PML) or granule cell neuronopathy (GCN). After immune reconstitution, some of these cases may show long-term persistence of JCV and delayed clinical improvement despite inflammation.
METHODS: We followed 4 patients with multiple sclerosis, who developed natalizumab-associated PML or GCN with regard to JC viral load and JCV-specific T-cell responses in the CNS. All of them experienced immune reconstitution inflammatory syndrome (IRIS), but in 2 cases JCV persisted > 21 months after IRIS accompanied by delayed clinical improvement.
RESULTS: Persistence of JCV was associated with a lack of JCV VP1-specific T-cell responses during immune reconstitution in 1 of the patients. Detailed analysis of the brain infiltrate in another patient with neuronal persistence of JCV revealed strong infiltration of CD8(+) T cells and clonal expansion of activated CD8(+) effector T cells with a CD4(dim) CD8(+) phenotype, both exhibiting exquisite specificity for conserved epitopes of JCV large T antigen. However, clearance of JCV was not efficient, because mutations in the major capsid protein VP1 caused reduced CD4(+) T-cell responses against the identified JCV variant and subsequently resulted in a decline of CD8(+) T-cell responses after IRIS.
INTERPRETATION: Our findings suggest that efficient CD4(+) T-cell recognition of neurotropic JCV variants is crucial to support CD8(+) T cells in combating JCV infection of the CNS.
© 2016 American Neurological Association.

Entities:  

Mesh:

Year:  2016        PMID: 26874214     DOI: 10.1002/ana.24574

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

Review 1.  [Progressive multifocal leukoencephalopathy].

Authors:  C Warnke; M P Wattjes; O Adams; H-P Hartung; R Martin; T Weber; M Stangel
Journal:  Nervenarzt       Date:  2016-12       Impact factor: 1.214

2.  Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient.

Authors:  Aabha Oza; Michael P Rettig; Phil Powell; Kathryn O'Brien; David B Clifford; Julie Ritchey; Leah Gehrs; Julia Hollaway; Eugene Major; Todd A Fehniger; Christopher A Miller; Patrick Soon-Shiong; Amy Rock; John F DiPersio
Journal:  Blood Adv       Date:  2020-06-09

Review 3.  Advances in Treatment of Progressive Multifocal Leukoencephalopathy.

Authors:  Raphaël Bernard-Valnet; Igor J Koralnik; Renaud Du Pasquier
Journal:  Ann Neurol       Date:  2021-09-07       Impact factor: 11.274

Review 4.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

5.  Neuroimmune Regulation of JC Virus by Intracellular and Extracellular Agnoprotein.

Authors:  Michael Craigie; Stephanie Cicalese; Ilker Kudret Sariyer
Journal:  J Neuroimmune Pharmacol       Date:  2017-11-20       Impact factor: 4.147

Review 6.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

7.  ViroFind: A novel target-enrichment deep-sequencing platform reveals a complex JC virus population in the brain of PML patients.

Authors:  Spyros Chalkias; Joshua M Gorham; Erica Mazaika; Michael Parfenov; Xin Dang; Steve DePalma; David McKean; Christine E Seidman; Jonathan G Seidman; Igor J Koralnik
Journal:  PLoS One       Date:  2018-01-23       Impact factor: 3.240

8.  Phenotypic and functional complexity of brain-infiltrating T cells in Rasmussen encephalitis.

Authors:  Faiez Al Nimer; Ivan Jelcic; Christian Kempf; Tom Pieper; Herbert Budka; Mireia Sospedra; Roland Martin
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-12-08

9.  Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod.

Authors:  Mitsuru Watanabe; Yuri Nakamura; Noriko Isobe; Masami Tanaka; Ayako Sakoda; Fumie Hayashi; Yuji Kawano; Ryo Yamasaki; Takuya Matsushita; Jun-Ichi Kira
Journal:  J Neuroinflammation       Date:  2020-07-09       Impact factor: 8.322

10.  BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study.

Authors:  Irene Cortese; Erin S Beck; Omar Al-Louzi; Joan Ohayon; Frances Andrada; Ikesinachi Osuorah; Jenifer Dwyer; B Jeanne Billioux; Nigar Dargah-Zada; Matthew K Schindler; Kyle Binder; Lauren Reoma; Gina Norato; Yoshimi Enose-Akahata; Bryan R Smith; Maria Chiara Monaco; Eugene O Major; Steven Jacobson; David Stroncek; Steven Highfill; Sandhya Panch; Daniel S Reich; John Barrett; Avindra Nath; Pawel Muranski
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 59.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.